세계의 희귀질환 유전자 검사 시장 : 질환 유형, 기술, 전문 분야, 최종 사용자별 예측(2025-2030년)

The Rare Disease Genetic Testing Market was valued at USD 1.33 billion in 2023, expected to reach USD 1.54 billion in 2024, and is projected to grow at a CAGR of 16.15%, to USD 3.80 billion by 2030.

Rare disease genetic testing involves diagnostic tests to identify gene mutations causing rare disorders, often affecting small patient populations scattered globally. This field's necessity stems from the critical role it plays in early diagnosis, personalized medicine, and providing targeted treatment options, especially when traditional therapies fail. Primarily applied in clinical and research settings, genetic testing supports informed clinical decisions, patient counseling, and drug development, with end-use scope spanning hospitals, diagnostic centers, and research institutes. The growth of genetic testing is driven by advances in genome sequencing technologies, increased awareness, and supportive government policies for rare disease research. Additionally, the increase in pharmaceutical investments and collaborations with diagnostic companies represents significant growth opportunities. A rise in demand for companion diagnostics and precision medicine amplifies market potential, while IT-enabled telehealth solutions ease testing accessibility.

However, the market faces limitations like high costs, regulatory challenges, ethical concerns around genetic data privacy, and limited awareness in developing regions. These challenges necessitate strategic pricing, clearer regulatory frameworks, and privacy protection advancements to foster market expansion. Innovation hotspots include the development of affordable sequencing technologies, integration of AI for predictive analytics, advanced bioinformatics tools for data interpretation, and personalized digital health platforms. Key recommendations to capitalize on market opportunities include fostering collaborations with molecular diagnostic firms, leveraging big data analytics, and establishing patient-centric solutions that enhance interaction between genetic counselors and patients. The nature of this market is research-intensive and highly specialized, requiring a keen understanding of genomic science and regulatory landscapes. The convergence of biotechnology, data analytics, and healthcare promises a generative ecosystem for novel therapeutic avenues and innovative care pathways, paving the way for breakthroughs in rare disease management and potentially disrupting the market landscape. By navigating regulatory and cost challenges, businesses can position themselves as leaders in this evolving field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Rare Disease Genetic Testing Market

The Rare Disease Genetic Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of Rare Genetic Disease and Need for Early & Rapid Diagnosis
  • Rising Use in Translational & Genomic Research for Identification of Novel Mutations
  • Government Initiatives for Diagnosis and Treatment of Rare Diseases
• Market Restraints
  • Ethical Concerns and Access to Limited Information on Rare Disease
• Market Opportunities
  • Advancements in Genetic Technology to Identify New Rare Disease Genes
  • Favorable Investments for Diagnosis of Rare Genetic Diseases
• Market Challenges
  • Stringent Regulations Associated with the Approval Process of New Rare Diseases Genetic Test

Porter's Five Forces: A Strategic Tool for Navigating the Rare Disease Genetic Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Rare Disease Genetic Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Rare Disease Genetic Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Rare Disease Genetic Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Rare Disease Genetic Testing Market

A detailed market share analysis in the Rare Disease Genetic Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Rare Disease Genetic Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Rare Disease Genetic Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Rare Disease Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Laboratory Corporation Of America Holdings, Biora Therapeutics, Inc., 3billion, Inc., Caris Life Sciences, Ambry Genetics Corporation, OPKO Health, Inc., Color Health, Inc., Quest Diagnostics Incorporated, Nonacus Limited, Integrated DNA Technologies, Inc. by Danaher Corporation, Myriad Genetics, Inc., Blueprint Genetics Oy, PerkinElmer Inc., Macrogen, Inc., F. Hoffmann-La Roche Ltd., Variantyx, Inc., Centogene N.V., Fulgent Genetics, Inc., Genomelink, Inc., Illumina, Inc., GeneDx, LLC, Invitae Corporation, Sanofi S.A., Helix OpCo, LLC, Arup Laboratories, The Cooper Companies, Inc., QIAGEN N.V., Realm IDX, Inc., Baylor Genetics, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Rare Disease Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Type, market is studied across Cancer, Cardiovascular Disorders, Dermatology Diseases, Endocrine & Metabolism Diseases, Hematology Diseases, Immunological Disorders, Musculoskeletal Disorders, and Neurological Disorders.
• Based on Technology, market is studied across Array Technology, FISH, Karyotyping, Next Generation Sequencing, PCR - Based Testing, and Sanger Sequencing. The Next Generation Sequencing is further studied across Whole Exome Sequencing and Whole Genome Sequencing.
• Based on Specialty, market is studied across Biochemical Genetic Tests, Chromosomal Genetic Tests, and Molecular Genetic Tests.
• Based on End-User, market is studied across Diagnostic Laboratories, Hospitals & Clinics, and Research Laboratories & CROs.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of Rare Genetic Disease and Need for Early & Rapid Diagnosis
    • 5.1.1.2. Rising Use in Translational & Genomic Research for Identification of Novel Mutations
    • 5.1.1.3. Government Initiatives for Diagnosis and Treatment of Rare Diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Ethical Concerns and Access to Limited Information on Rare Disease
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in Genetic Technology to Identify New Rare Disease Genes
    • 5.1.3.2. Favorable Investments for Diagnosis of Rare Genetic Diseases
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent Regulations Associated with the Approval Process of New Rare Diseases Genetic Test
• 5.2. Market Segmentation Analysis
  • 5.2.1. Disease Type: Development of advanced tests to cater to the screening needs of rare genetic diseases
  • 5.2.2. End-User: Emerging studies on rare genetic testing in research laboratories in academic institutes
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Rare Disease Genetic Testing Market, by Disease Type

• 6.1. Introduction
• 6.2. Cancer
• 6.3. Cardiovascular Disorders
• 6.4. Dermatology Diseases
• 6.5. Endocrine & Metabolism Diseases
• 6.6. Hematology Diseases
• 6.7. Immunological Disorders
• 6.8. Musculoskeletal Disorders
• 6.9. Neurological Disorders

7. Rare Disease Genetic Testing Market, by Technology

• 7.1. Introduction
• 7.2. Array Technology
• 7.3. FISH
• 7.4. Karyotyping
• 7.5. Next Generation Sequencing
  • 7.5.1. Whole Exome Sequencing
  • 7.5.2. Whole Genome Sequencing
• 7.6. PCR - Based Testing
• 7.7. Sanger Sequencing

8. Rare Disease Genetic Testing Market, by Specialty

• 8.1. Introduction
• 8.2. Biochemical Genetic Tests
• 8.3. Chromosomal Genetic Tests
• 8.4. Molecular Genetic Tests

9. Rare Disease Genetic Testing Market, by End-User

• 9.1. Introduction
• 9.2. Diagnostic Laboratories
• 9.3. Hospitals & Clinics
• 9.4. Research Laboratories & CROs

10. Americas Rare Disease Genetic Testing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Rare Disease Genetic Testing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Rare Disease Genetic Testing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Burjeel Holdings To Launch Rare Disease Research & Development Project 'Nader' In Partnership With US-Based Bridgebio Pharma
  • 13.3.2. NIH Launches USD 140 Million Effort To Investigate Genetic Variation In Normal Human Cells And Tissues
  • 13.3.3. CENTOGENE Launches NEW CentoGenome, A Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases

Companies Mentioned

• 1. Laboratory Corporation Of America Holdings
• 2. Biora Therapeutics, Inc.
• 3. 3billion, Inc.
• 4. Caris Life Sciences
• 5. Ambry Genetics Corporation
• 6. OPKO Health, Inc.
• 7. Color Health, Inc.
• 8. Quest Diagnostics Incorporated
• 9. Nonacus Limited
• 10. Integrated DNA Technologies, Inc. by Danaher Corporation
• 11. Myriad Genetics, Inc.
• 12. Blueprint Genetics Oy
• 13. PerkinElmer Inc.
• 14. Macrogen, Inc.
• 15. F. Hoffmann-La Roche Ltd.
• 16. Variantyx, Inc.
• 17. Centogene N.V.
• 18. Fulgent Genetics, Inc.
• 19. Genomelink, Inc.
• 20. Illumina, Inc.
• 21. GeneDx, LLC
• 22. Invitae Corporation
• 23. Sanofi S.A.
• 24. Helix OpCo, LLC
• 25. Arup Laboratories
• 26. The Cooper Companies, Inc.
• 27. QIAGEN N.V.
• 28. Realm IDX, Inc.
• 29. Baylor Genetics
• 30. Thermo Fisher Scientific Inc.